In a randomised, 48-week double-blind, controlled study of tenofovir disoproxil 245 mg (as fumarate) in patients co-infected with HIV-1 and chronic hepatitis B with prior lamivudine experience (study ACTG 5127), the mean serum HBV DNA levels at baseline in patients randomised to the tenofovir